

Company Registration No. 10071438 (England and Wales)

**STAR TISSUE HOLDINGS LIMITED**  
**ANNUAL REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 SEPTEMBER 2021**

# STAR TISSUE HOLDINGS LIMITED

## COMPANY INFORMATION

---

<b>Directors</b>	Abid Ditta Khalid Saifullah Sajid Saifullah
<b>Company number</b>	10071438
<b>Registered office</b>	Waterfall Street Blackburn Lancashire BB2 2BN
<b>Auditor</b>	Pierce C A Limited Mentor House Ainsworth Street Blackburn Lancashire BB1 6AY
<b>Business address</b>	Waterfall Street Blackburn Lancashire BB2 2BN
<b>Bankers</b>	HSBC Bank plc 60 Church Street Blackburn Lancashire BB1 5AS

---

# STAR TISSUE HOLDINGS LIMITED

## CONTENTS

---

	Page
Strategic report	1 - 2
Directors' report	3 - 4
Independent auditor's report	5 - 7
Group statement of comprehensive income	8
Group balance sheet	9
Company balance sheet	10
Group statement of changes in equity	11
Company statement of changes in equity	12
Group statement of cash flows	13
Notes to the financial statements	14 - 30

---

# STAR TISSUE HOLDINGS LIMITED

## STRATEGIC REPORT

**FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

The directors present the strategic report and financial statements for the year ended 30 September 2021.

### **Fair review of the business**

Our principal trading activity has been the manufacture of hygiene paper products for the Away from Home (AFH) market which includes the food, leisure, hospitality, office, industry and medical sectors.

COVID caused us many disruptions this year but we used the periods of low demand to focus on investing in people and increasing efficiencies. Maintaining our investments in place, people, processes and productivity will strengthen the company to be better placed to meet the increased demand in the post-Covid market.

We have invested heavily in the site as part of our Future Factory programme. A brand new waste extraction system was installed to automatically remove waste from the production lines.

A new access and security system was installed in all of the buildings onsite. The staff canteen, locker rooms and workshops were refurbished to a very high standard representing our commitment to staff welfare.

This is ongoing as next year we are looking at adding new offices, further extensions to our production facility, a new gatehouse and the resurfacing of our service yard. Also, plans are in place to further reduce our carbon footprint by replacing our gas powered FLT's with electric FLT's.

With the appointment of a new production manager and health and safety manager, a full programme of training has been introduced to develop effective and safe teams. A new rewards programme is being developed and will be introduced in the new year.

Our SAP system was upgraded to the latest version and new process innovations are being explored to further integrate our machines with our ERP system. Utilising IOT and AI, it is possible to gather much more data to help with maintenance and production planning.

We have put on order two end of line pallet stacking and pallet handling systems to fully automate Line 1 and Line 4. These should be fully operational in early 2022.

### **Business environment**

In light of the ongoing ambiguity related to the pandemic, demand has been very mixed this year with periods of heightened demand in our products followed by periods of reduced demand in sectors that were adversely affected by the pandemic. Overall, demand remained consistent for consumer tissue, while we experienced a temporary reduction in demand for Away from Home products given the impact that Covid-19 and the resulting lockdowns had on businesses, in particular restaurants, leisure, hotels and schools. This temporary reduction in demand was offset by increases in demand from the online, wholesale and health sectors. We have taken steps to adjust production capacity to meet these increasing demands from these sectors. Our wide range of products and diverse customer base enabled us to mitigate troughs in demand and maintain our turnover close to our target for this year (£28m). The planned investments will provide much needed capacity next year to meet the increased demands of hygiene paper products once the sectors fully open back up. We are projecting to grow by 25-30% next year if we have no further lockdowns. The directors continue to assess the important risks faced by the group including risks associated with Brexit and COVID. The directors plan to continue with the strategy which has led to the satisfactory results.

We are expecting a difficult business environment ahead with continued disruption in the supply chain caused by COVID impacting on all supply routes, container shortages, limited availability of transport and port congestion. A rise in energy costs, shipping/transport costs, packaging and raw materials will continue to push up manufacturing costs and costs of materials in the coming year. To mitigate this, we have built up good stock levels, continue to invest in improving productivity and enhance our recruitment and retention programmes. No doubt we will implement price increases to recover these costs. Our strong trading relationships locally and globally with suppliers and customers puts us in a strong position to mitigate these challenges and we are confident that we will come out of this period as a very resilient group.

# **STAR TISSUE HOLDINGS LIMITED**

## **STRATEGIC REPORT (CONTINUED)**

***FOR THE YEAR ENDED 30 SEPTEMBER 2021***

---

### **Strategic management**

Our strategy is to continue to grow the business through strategic investments that will introduce new products to our product range enhancing our product offering and providing a one stop shop for our customers. In the coming year our investments will be focussed on productivity, automation and further site improvements. We will continue to maintain and strengthen our balance sheet with a view to exploring bigger investment opportunities that will increase our bottom line and market share. The group has developed a strong relationship with its finance providers which has resulted in a generous working capital facility agreed at competitive borrowing rates to help fund continued growth. The group has continued to recruit the best people that are able to grow and develop in a fast growing business where productivity and innovation drives improvements throughout the business.

### **Key performance indicators**

The directors continue to measure the performance of the group by reference to turnover growth, overall gross profit and net profitability of its subsidiary which are monitored on a monthly basis. We are pleased to report that the business has demonstrated its resilience in this challenging climate by maintaining its turnover and profitability.

On behalf of the board

Khalid Saifullah  
**Director**

16 February 2022

# STAR TISSUE HOLDINGS LIMITED

## DIRECTORS' REPORT

### FOR THE YEAR ENDED 30 SEPTEMBER 2021

---

The directors present their annual report and financial statements for the year ended 30 September 2021.

#### Principal activities

The principal activity of the company is that of a parent company coordinating the activities of the group, whose trading subsidiary's principal activity is that of the manufacture and distribution of quality hygiene paper products.

#### Results and dividends

The results for the year are set out on page 8.

Ordinary dividends were paid amounting to £379,500. The directors do not recommend payment of a further dividend.

#### Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Abid Ditta  
Khalid Saifullah  
Sajid Saifullah

#### Auditor

The auditor, Pierce C.A. Limited, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

#### Statement of directors' responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the ;
- prepare the on the going concern basis unless it is inappropriate to presume that the group and company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group's and company's transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

**STAR TISSUE HOLDINGS LIMITED**

**DIRECTORS' REPORT (CONTINUED)**

***FOR THE YEAR ENDED 30 SEPTEMBER 2021***

---

On behalf of the board

Khalid Saifullah

**Director**

16 February 2022

# STAR TISSUE HOLDINGS LIMITED

## INDEPENDENT AUDITOR'S REPORT

### TO THE MEMBERS OF STAR TISSUE HOLDINGS LIMITED

---

#### Opinion

We have audited the financial statements of Star Tissue Holdings Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 30 September 2021 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent company's affairs as at 30 September 2021 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

#### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

#### Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.



# **STAR TISSUE HOLDINGS LIMITED**

## **INDEPENDENT AUDITOR'S REPORT (CONTINUED)**

### **TO THE MEMBERS OF STAR TISSUE HOLDINGS LIMITED**

---

#### **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.

#### **Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report and the directors' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

#### **Responsibilities of directors**

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

#### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

## **STAR TISSUE HOLDINGS LIMITED**

### **INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS OF STAR TISSUE HOLDINGS LIMITED**

---

In identifying and assessing risks of material misstatement in respect of irregularities we considered the following:

- The nature of the industry and the group and company's control environment.
- Results of our enquiries of management.
- The group and company's procedures and controls on compliance with laws and regulations and the risks of fraud.
- Discussions among the audit engagement team concerning potential indicators of fraud.

We are also required to perform specific procedures to respond to the risk of management override.

As a result of our audit procedures we did not identify a material risk of fraud or other non-compliance with laws and regulations.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

#### **Use of our report**

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

**Paul Moulding (Senior Statutory Auditor)**  
**For and on behalf of Pierce C A Limited**

16 February 2022

**Statutory Auditor**

Mentor House  
Ainsworth Street  
Blackburn  
Lancashire  
BB1 6AY

# STAR TISSUE HOLDINGS LIMITED

## GROUP STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 30 SEPTEMBER 2021

	Notes	2021 £	2020 £
<b>Turnover</b>	<b>3</b>	28,810,972	28,890,061
Cost of sales		(22,655,958)	(22,488,209)
<b>Gross profit</b>		<b>6,155,014</b>	<b>6,401,852</b>
Administrative expenses		(3,169,020)	(2,401,215)
Other operating income		146,446	160,974
<b>Operating profit</b>	<b>4</b>	<b>3,132,440</b>	<b>4,161,611</b>
Interest payable and similar expenses	<b>8</b>	(57,827)	(40,663)
<b>Profit before taxation</b>		<b>3,074,613</b>	<b>4,120,948</b>
Tax on profit	<b>9</b>	(781,611)	(749,073)
<b>Profit for the financial year</b>		<b>2,293,002</b>	<b>3,371,875</b>

Profit and total comprehensive income for the year is all attributable to the owners of the parent company.

# STAR TISSUE HOLDINGS LIMITED

## GROUP BALANCE SHEET

AS AT 30 SEPTEMBER 2021

	Notes	2021 £	£	2020 £	£
<b>Fixed assets</b>					
Goodwill	11		-		12,180
Tangible assets	12		6,984,211		5,558,613
			<u>6,984,211</u>		<u>5,570,793</u>
<b>Current assets</b>					
Stocks	15	2,605,865		1,780,263	
Debtors	16	8,090,674		5,600,965	
Cash at bank and in hand		4,648,675		4,693,127	
		<u>15,345,214</u>		<u>12,074,355</u>	
<b>Creditors: amounts falling due within one year</b>	17	(6,719,596)		(5,726,614)	
<b>Net current assets</b>			<u>8,625,618</u>		<u>6,347,741</u>
<b>Total assets less current liabilities</b>			15,609,829		11,918,534
<b>Creditors: amounts falling due after more than one year</b>	18		(2,288,883)		(1,053,915)
<b>Provisions for liabilities</b>					
Deferred tax liability	21	984,630		441,805	
		<u>(984,630)</u>		<u>(441,805)</u>	
<b>Net assets</b>			<u>12,336,316</u>		<u>10,422,814</u>
<b>Capital and reserves</b>					
Called up share capital	24		90		90
Revaluation reserve			198,416		200,676
Capital redemption reserve			10		10
Profit and loss reserves			12,137,800		10,222,038
<b>Total equity</b>			<u>12,336,316</u>		<u>10,422,814</u>

The financial statements were approved by the board of directors and authorised for issue on 16 February 2022 and are signed on its behalf by:

Khalid Saifullah  
Director

# STAR TISSUE HOLDINGS LIMITED

## COMPANY BALANCE SHEET

AS AT 30 SEPTEMBER 2021

	Notes	2021 £	£	2020 £	£
<b>Fixed assets</b>					
Tangible assets	12	2,008,941		1,982,065	
Investments	13	100		100	
		<u>2,009,041</u>		<u>1,982,165</u>	
<b>Current assets</b>					
Debtors	16	878,543		379,500	
Cash at bank and in hand		2,634,550		2,531,221	
		<u>3,513,093</u>		<u>2,910,721</u>	
<b>Creditors: amounts falling due within one year</b>	17	<u>(35,527)</u>		<u>(48,451)</u>	
<b>Net current assets</b>			3,477,566		2,862,270
<b>Total assets less current liabilities</b>			<u>5,486,607</u>		<u>4,844,435</u>
<b>Creditors: amounts falling due after more than one year</b>	18		(516,453)		(546,323)
<b>Provisions for liabilities</b>					
Deferred tax liability	21	19,343		-	
		<u>(19,343)</u>		<u>-</u>	
<b>Net assets</b>			<u>4,950,811</u>		<u>4,298,112</u>
<b>Capital and reserves</b>					
Called up share capital	24		90		90
Capital redemption reserve			10		10
Profit and loss reserves			4,950,711		4,298,012
<b>Total equity</b>			<u>4,950,811</u>		<u>4,298,112</u>

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company's profit for the year was £1,032,199 (2020 - £2,486,477).

The financial statements were approved by the board of directors and authorised for issue on 16 February 2022 and are signed on its behalf by:

Khalid Saifullah  
Director

Company Registration No. 10071438

# STAR TISSUE HOLDINGS LIMITED

## GROUP STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 30 SEPTEMBER 2021

		Share capital	Revaluation reserve	Capital redemption reserve	Profit and loss reserves	Total
	Notes	£	£	£	£	£
<b>Balance at 1 October 2019</b>		90	202,939	10	7,227,400	7,430,439
<b>Year ended 30 September 2020:</b>						
Profit and total comprehensive income for the year		-	-	-	3,371,875	3,371,875
Dividends	10	-	-	-	(379,500)	(379,500)
Transfers		-	(2,263)	-	2,263	-
<b>Balance at 30 September 2020</b>		90	200,676	10	10,222,038	10,422,814
<b>Year ended 30 September 2021:</b>						
Profit and total comprehensive income for the year		-	-	-	2,293,002	2,293,002
Dividends	10	-	-	-	(379,500)	(379,500)
Transfers		-	(2,260)	-	2,260	-
<b>Balance at 30 September 2021</b>		90	198,416	10	12,137,800	12,336,316

# STAR TISSUE HOLDINGS LIMITED

## COMPANY STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 30 SEPTEMBER 2021

		Share capital	Capital redemption reserve	Profit and loss reserves	Total
	Notes	£	£	£	£
<b>Balance at 1 October 2019</b>		90	10	2,191,035	2,191,135
<b>Year ended 30 September 2020:</b>					
Profit and total comprehensive income for the year		-	-	2,486,477	2,486,477
Dividends	10	-	-	(379,500)	(379,500)
<b>Balance at 30 September 2020</b>		90	10	4,298,012	4,298,112
<b>Year ended 30 September 2021:</b>					
Profit and total comprehensive income for the year		-	-	1,032,199	1,032,199
Dividends	10	-	-	(379,500)	(379,500)
<b>Balance at 30 September 2021</b>		90	10	4,950,711	4,950,811

# STAR TISSUE HOLDINGS LIMITED

## GROUP STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 30 SEPTEMBER 2021

	Notes	2021 £	£	2020 £	£
<b>Cash flows from operating activities</b>					
Cash generated from operations	29	2,785,712		5,137,107	
Interest paid		(57,827)		(40,663)	
Income taxes paid		(871,484)		(312,970)	
<b>Net cash inflow from operating activities</b>		1,856,401		4,783,474	
<b>Investing activities</b>					
Purchase of tangible fixed assets		(1,280,917)		(1,909,123)	
Payments for loans made		(498,000)		(379,500)	
<b>Net cash used in investing activities</b>		(1,778,917)		(2,288,623)	
<b>Financing activities</b>					
Repayment of bank loans		(30,291)		(29,347)	
Advances/(payment) of finance leases obligations		841,413		(322,095)	
Dividends paid to equity shareholders		(379,500)		(379,500)	
<b>Net cash generated from/(used in) financing activities</b>		431,622		(730,942)	
<b>Net increase in cash and cash equivalents</b>		509,106		1,763,909	
Cash and cash equivalents at beginning of year		4,139,569		2,375,660	
<b>Cash and cash equivalents at end of year</b>		4,648,675		4,139,569	
<b>Relating to:</b>					
Cash at bank and in hand		4,648,675		4,693,127	
Bank overdrafts included in creditors payable within one year		-		(553,558)	



# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

**FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

### **1 Accounting policies**

#### **Company information**

Star Tissue Holdings Limited ("the company") is a private limited company domiciled and incorporated in England and Wales. The registered office is Waterfall Street, Blackburn, Lancashire, BB2 2BN.

The group consists of Star Tissue Holdings Limited and all of its subsidiaries.

#### **1.1 Accounting convention**

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, as modified to include the revaluation of the group's leasehold land and buildings. The principal accounting policies adopted are set out below.

#### **1.2 Basis of consolidation**

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess or deficit of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill or negative goodwill respectively. The acquired negative goodwill arising on consolidation has been written off in full in the period of acquisition. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.

The consolidated group financial statements consist of the financial statements of the parent company Star Tissue Holdings Limited together with all entities controlled by the parent company (its subsidiaries) and the group's share of its interests in joint ventures and associates.

All financial statements are made up to 30 September 2021. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

#### **1.3 Going concern**

At the time of approving the financial statements, the directors have a reasonable expectation that the company and group have adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

In forming their assessment, the directors have given due regard to the worldwide Coronavirus pandemic, Covid-19, and its impact on the group. The directors are of the opinion that the group has adequate resources and that they have put in place the necessary safeguards to continue trading through this period.

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 1 Accounting policies

(Continued)

#### 1.4 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

#### 1.5 Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 15 years.

#### 1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings	2% straight line
Plant and equipment	7.5% straight line
Fixtures and fittings	15% straight line
Motor vehicles	20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

#### 1.7 Fixed asset investments

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

#### 1.8 Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

#### 1.9 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

---

### 1 Accounting policies

(Continued)

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

#### 1.10 Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.11 Financial instruments

The group has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Impairment of financial assets**

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

##### **Classification of financial liabilities**

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

Basic financial liabilities, including creditors, bank loans and loans from fellow group companies, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

#### 1.12 Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

#### 1.13 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

---

### 1 Accounting policies

(Continued)

#### **Current tax**

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible.

#### **Deferred tax**

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

The group's liability for tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

#### **1.14 Employee benefits**

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

#### **1.15 Retirement benefits**

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

#### **1.16 Leases**

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss on a straight line basis.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

#### **1.17 Government grants**

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

Grants received in respect of capital expenditure are amortised on a straight line basis at 7.5% per annum in line with the depreciation policy on the plant and machinery assets to which they relate.

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 1 Accounting policies

(Continued)

#### 1.18 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

### 2 Judgements and key sources of estimation uncertainty

In the application of the group's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

#### Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

#### Stocks provisions

Stocks provision assessments are considered to be a key accounting estimate for which management review the results of regular stock counts in determining the extent to which provisions should be made against slow-moving or obsolete stocks.

#### Debtor recoverability

Debtor recoverability is considered to be a key accounting estimate for which management continuously monitor customer debt recoveries through credit control procedures and make assessments regarding the extent to which bad debt provisions are considered necessary.

### 3 Turnover and other revenue

	2021 £	2020 £
<b>Turnover analysed by class of business</b>		
Manufacture and supply of quality hygiene paper products	28,810,972	28,890,061
	<u>                    </u>	<u>                    </u>
	2021 £	2020 £
<b>Other significant revenue</b>		
Grants received	35,560	35,560
Covid-19 JRS monies receivable	110,886	121,522
	<u>                    </u>	<u>                    </u>

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 3 Turnover and other revenue (Continued)

	2021 £	2020 £
<b>Turnover analysed by geographical market</b>		
United Kingdom	28,030,624	28,370,720
Europe	780,348	519,341
	<u>28,810,972</u>	<u>28,890,061</u>

### 4 Operating profit

	2021 £	2020 £
Operating profit for the year is stated after charging/(crediting):		
Exchange losses/(gains)	130,989	(137,540)
Government grants	(146,446)	(157,082)
Depreciation of owned tangible fixed assets	247,084	234,340
Depreciation of tangible fixed assets held under finance leases	247,756	94,492
Amortisation of intangible assets	12,180	12,204
Cost of stocks recognised as an expense	20,218,391	20,242,503
Operating lease charges	156,459	150,994
	<u>20,218,391</u>	<u>20,242,503</u>

### 5 Auditor's remuneration

	2021 £	2020 £
Fees payable to the company's auditor and associates:		
<b>For audit services</b>		
Audit of the financial statements of the group and company	2,500	2,500
Audit of the financial statements of the company's subsidiaries	5,500	5,500
	<u>8,000</u>	<u>8,000</u>

### 6 Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

	Group 2021 Number	2020 Number	Company 2021 Number	2020 Number
Administration	3	3	3	3
Production, sales and marketing	132	125	-	-
Total	<u>135</u>	<u>128</u>	<u>3</u>	<u>3</u>

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 6 Employees (Continued)

Their aggregate remuneration comprised:

	Group 2021 £	2020 £	Company 2021 £	2020 £
Wages and salaries	2,614,316	2,325,848	-	-
Social security costs	197,219	169,518	-	-
Pension costs	42,134	37,291	-	-
	<u>2,853,669</u>	<u>2,532,657</u>	<u>-</u>	<u>-</u>

### 7 Directors' remuneration

	2021 £	2020 £
Remuneration for qualifying services	<u>37,847</u>	<u>37,710</u>

Dividends paid to the directors during the year amounted to £379,500 (2020 - £379,500).

### 8 Interest payable and similar expenses

	2021 £	2020 £
<b>Interest on financial liabilities measured at amortised cost:</b>		
Interest on bank overdrafts and loans	<u>57,827</u>	<u>40,663</u>

### 9 Taxation

	2021 £	2020 £
<b>Current tax</b>		
UK corporation tax on profits for the current period	238,786	577,916
Adjustments in respect of prior periods	-	(41,293)
Total current tax	<u>238,786</u>	<u>536,623</u>
<b>Deferred tax</b>		
Origination and reversal of timing differences	<u>542,825</u>	<u>212,450</u>
Total tax charge	<u>781,611</u>	<u>749,073</u>

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 9 Taxation

(Continued)

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

	2021 £	2020 £
Profit before taxation	3,074,613	4,120,948
Expected tax charge based on the standard rate of corporation tax in the UK of 19.00% (2020: 19.00%)	584,176	782,980
Tax effect of expenses that are not deductible in determining taxable profit	86	142
Adjustments in respect of prior years	-	(41,293)
Effect of change in corporation tax rate	236,311	26,983
Depreciation on assets not qualifying for tax allowances	6,218	6,219
Amortisation on assets not qualifying for tax allowances	2,314	2,319
Research and development tax credit	-	(33,518)
Other non-reversing timing differences	53	(1,515)
Enhanced capital allowances claimed	(54,303)	-
Government grant income	6,756	6,756
Taxation charge	781,611	749,073

### 10 Dividends

	2021 £	2020 £
Recognised as distributions to equity holders:		
Interim paid	379,500	379,500

### 11 Intangible fixed assets

Group	Goodwill £	Negative goodwill £	Total £
<b>Cost</b>			
At 1 October 2020 and 30 September 2021	67,098	(2,310,092)	(2,242,994)
<b>Amortisation and impairment</b>			
At 1 October 2020	54,918	(2,310,092)	(2,255,174)
Amortisation charged for the year	12,180	-	12,180
At 30 September 2021	67,098	(2,310,092)	(2,242,994)



# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 11 Intangible fixed assets (Continued)

#### Carrying amount

At 30 September 2021	-	-	-
At 30 September 2020	12,180	-	12,180

The company had no intangible fixed assets at 30 September 2021 or 30 September 2020.

### 12 Tangible fixed assets

Group	Leasehold land and buildings	Plant and equipment	Fixtures and fittings	Motor vehicles	Total
	£	£	£	£	£
<b>Cost or valuation</b>					
At 1 October 2020	2,045,173	4,471,102	251,571	-	6,767,846
Additions	67,902	1,804,931	16,605	31,000	1,920,438
At 30 September 2021	2,113,075	6,276,033	268,176	31,000	8,688,284
<b>Depreciation and impairment</b>					
At 1 October 2020	63,108	968,092	178,033	-	1,209,233
Depreciation charged in the year	41,026	420,770	28,136	4,908	494,840
At 30 September 2021	104,134	1,388,862	206,169	4,908	1,704,073
<b>Carrying amount</b>					
At 30 September 2021	2,008,941	4,887,171	62,007	26,092	6,984,211
At 30 September 2020	1,982,065	3,503,010	73,538	-	5,558,613

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

12	Tangible fixed assets	(Continued)
	Company	Leasehold land and buildings
		£
	<b>Cost or valuation</b>	
	At 1 October 2020	2,045,173
	Additions	67,902
	At 30 September 2021	2,113,075
	<b>Depreciation and impairment</b>	
	At 1 October 2020	63,108
	Depreciation charged in the year	41,026
	At 30 September 2021	104,134
	<b>Carrying amount</b>	
	At 30 September 2021	2,008,941
	At 30 September 2020	1,982,065

The carrying value of land and buildings comprises:

	Group 2021 £	2020 £	Company 2021 £	2020 £
Long leasehold	2,008,941	1,982,065	2,008,941	1,982,065

The net carrying value of tangible fixed assets includes the following in respect of assets held under finance leases or hire purchase contracts.

	Group 2021 £	2020 £	Company 2021 £	2020 £
Plant and equipment	2,900,148	997,796	-	-

Land and buildings includes a valuation of £1,700,000 carried out at 30 September 2018 by Knight Frank LLP, independent valuers not connected with the company on the basis of market value, plus additions subsequent to this date carried at historic cost. The valuation conformed to International Valuation Standards and was based on recent market transactions on arm's length terms for similar properties.

Land and buildings are carried at valuation. If land and buildings were measured using the cost model, the carrying amounts for the group and company would have been approximately £1,810,543 (2020 - £1,781,389), being cost £1,999,722 (2020 - £1,931,820) and depreciation £189,179 (2020 - £150,431).

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 13 Fixed asset investments

	Notes	Group 2021 £	2020 £	Company 2021 £	2020 £
Investments in subsidiaries	14	-	-	100	100

#### Movements in fixed asset investments Company

Shares in  
subsidiaries  
£

#### Cost or valuation

At 1 October 2020 and 30 September 2021

100

#### Carrying amount

At 30 September 2021

100

At 30 September 2020

100

### 14 Subsidiaries

Details of the company's subsidiaries at 30 September 2021 are as follows:

Name of undertaking	Registered office	Class of shares held	% Held Direct
Star Tissue UK Limited	Waterfall Street, Blackburn BB2 2BN	Ordinary	100.00

### 15 Stocks

	Group 2021 £	2020 £	Company 2021 £	2020 £
Raw materials and consumables	1,781,770	1,324,067	-	-
Work in progress	23,740	16,656	-	-
Finished goods and goods for resale	800,355	439,540	-	-
	2,605,865	1,780,263	-	-

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 16 Debtors

	Group 2021	2020	Company 2021	2020
	£	£	£	£
<b>Amounts falling due within one year:</b>				
Trade debtors	6,495,453	4,135,507	-	-
Corporation tax recoverable	87,506	41,293	-	-
Other debtors	1,378,023	1,262,241	878,543	379,500
Prepayments and accrued income	129,692	161,924	-	-
	<u>8,090,674</u>	<u>5,600,965</u>	<u>878,543</u>	<u>379,500</u>

### 17 Creditors: amounts falling due within one year

	Notes	Group 2021	2020	Company 2021	2020
		£	£	£	£
Bank loans and overdrafts	19	29,844	583,823	29,844	30,265
Obligations under finance leases	20	400,603	220,067	-	-
Trade creditors		4,569,567	3,326,208	-	-
Corporation tax payable		-	586,485	1,682	11,204
Other taxation and social security		1,019,576	909,912	-	2,982
Other creditors		8,600	7,621	-	-
Accruals and deferred income		691,406	92,498	4,001	4,000
		<u>6,719,596</u>	<u>5,726,614</u>	<u>35,527</u>	<u>48,451</u>

### 18 Creditors: amounts falling due after more than one year

	Notes	Group 2021	2020	Company 2021	2020
		£	£	£	£
Bank loans and overdrafts	19	516,453	546,323	516,453	546,323
Obligations under finance leases	20	1,612,718	312,320	-	-
Government grants	22	159,712	195,272	-	-
		<u>2,288,883</u>	<u>1,053,915</u>	<u>516,453</u>	<u>546,323</u>

Amounts included above which fall due after five years are as follows:

Payable by instalments	389,400	416,134	389,400	416,134
	<u>389,400</u>	<u>416,134</u>	<u>389,400</u>	<u>416,134</u>

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 19 Loans and overdrafts

	Group 2021 £	2020 £	Company 2021 £	2020 £
Bank loans	546,297	576,588	546,297	576,588
Bank overdrafts	-	553,558	-	-
	<u>546,297</u>	<u>1,130,146</u>	<u>546,297</u>	<u>576,588</u>
Payable within one year	29,844	583,823	29,844	30,265
Payable after one year	<u>516,453</u>	<u>546,323</u>	<u>516,453</u>	<u>546,323</u>

The group's bankers, HSBC Bank plc, hold as security fixed and floating charges over all of the group's property and other assets, together with a cross guarantee over all group borrowings.

The group also operates an invoice discounting facility with HSBC Invoice Finance (UK) Limited whereby working capital is provided to the subsidiary company under an agreement to purchase that company's eligible debts, against which fixed and floating charges have been granted over the subsidiary company's assets.

The group bank loan borrowings carry interest payable at a rate of 2.5% over the bank's base rate.

### 20 Finance lease obligations

	Group 2021 £	2020 £	Company 2021 £	2020 £
Future minimum lease payments due under finance leases:				
Within one year	400,603	220,067	-	-
In two to five years	<u>1,612,718</u>	<u>312,320</u>	<u>-</u>	<u>-</u>
	<u>2,013,321</u>	<u>532,387</u>	<u>-</u>	<u>-</u>

Obligations under finance lease and hire purchase agreements are secured by fixed charges on the assets concerned.

### 21 Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

	Liabilities 2021 £	Liabilities 2020 £
Group		
Accelerated capital allowances	<u>984,630</u>	<u>441,805</u>

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 21 Deferred taxation (Continued)

	Liabilities 2021 £	Liabilities 2020 £
<b>Company</b>		
Accelerated capital allowances	19,343	-
	<u>          </u>	<u>          </u>
	<b>Group 2021 £</b>	<b>Company 2021 £</b>
<b>Movements in the year:</b>		
Liability at 1 October 2020	441,805	-
Charge to profit or loss	542,825	19,343
	<u>          </u>	<u>          </u>
Liability at 30 September 2021	984,630	19,343
	<u>          </u>	<u>          </u>

### 22 Government grants

	Group 2021 £	2020 £	Company 2021 £	2020 £
Arising from government grants	159,712	195,272	-	-
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>

Grants have been made available under the Regional Growth Fund to facilitate the acquisition of items of plant and machinery.

### 23 Retirement benefit schemes

	2021 £	2020 £
<b>Defined contribution schemes</b>		
Charge to profit or loss in respect of defined contribution schemes	42,134	37,291
	<u>          </u>	<u>          </u>

Defined contribution pension schemes are operated for all qualifying employees. The assets of these schemes are held separately from those of the group in independently administered funds.

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 24 Share capital

Group and company	2021	2020	2021	2020
Ordinary share capital	Number	Number	£	£
Issued and fully paid				
Ordinary 'A' shares of £1 each	40	40	40	40
Ordinary 'B' shares of £1 each	25	25	25	25
Ordinary 'C' shares of £1 each	25	25	25	25
	<u>90</u>	<u>90</u>	<u>90</u>	<u>90</u>

### 25 Operating lease commitments

#### Lessee

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	Group	2020	Company	2020
	2021		2021	
	£	£	£	£
Within one year	185,952	185,690	-	-
Between two and five years	145,534	302,716	-	-
	<u>331,486</u>	<u>488,406</u>	<u>-</u>	<u>-</u>

### 26 Capital commitments

Amounts contracted for but not provided in the financial statements:

	Group	2020	Company	2020
	2021		2021	
	£	£	£	£
Acquisition of tangible fixed assets	129,343	462,366	129,343	-
	<u>129,343</u>	<u>462,366</u>	<u>129,343</u>	<u>-</u>

# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 27 Directors' transactions

Advances or credits have been granted by the group to its directors as follows:

Description	% Rate	Opening balance £	Amounts advanced £	Amounts repaid £	Closing balance £
Abid Ditta - Director's loan	-	136,500	312,500	(136,500)	312,500
Khalid Saifullah - Director's loan	-	129,000	305,000	(129,000)	305,000
Sajid Saifullah - Director's loan	-	114,000	260,000	(114,000)	260,000
		<u>379,500</u>	<u>877,500</u>	<u>(379,500)</u>	<u>877,500</u>

### 28 Controlling party

The company is ultimately controlled by the directors by virtue of their shareholdings in the company.

### 29 Cash generated from group operations

	2021 £	2020 £
Profit for the year after tax	2,293,002	3,371,875
<b>Adjustments for:</b>		
Taxation charged	781,611	749,073
Finance costs	57,827	40,663
Amortisation and impairment of intangible assets	12,180	12,204
Depreciation and impairment of tangible fixed assets	494,840	328,832
<b>Movements in working capital:</b>		
(Increase)/decrease in stocks	(825,602)	377,494
(Increase)/decrease in debtors	(1,945,496)	804,693
Increase/(decrease) in creditors	1,952,910	(512,167)
Decrease in deferred income	(35,560)	(35,560)
<b>Cash generated from operations</b>	<u>2,785,712</u>	<u>5,137,107</u>



# STAR TISSUE HOLDINGS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

### 30 Analysis of changes in net funds - group

	1 October 2020	Cash flows	New finance leases	30 September 2021
	£	£	£	£
Cash at bank and in hand	4,693,127	(44,452)	-	4,648,675
Bank overdrafts	(553,558)	553,558	-	-
	<u>4,139,569</u>	<u>509,106</u>	<u>-</u>	<u>4,648,675</u>
Borrowings excluding overdrafts	(576,588)	30,291	-	(546,297)
Obligations under finance leases	(532,387)	(841,413)	(639,521)	(2,013,321)
	<u>3,030,594</u>	<u>(302,016)</u>	<u>(639,521)</u>	<u>2,089,057</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.